DV
Dividend Vision

SBIO — ALPS Medical Breakthroughs ETF

ALPS Medical Breakthroughs ETF (SBIO)

SBIO carries a 0.50% expense ratio. Total return is 194.2% over the past 11.6 years, 163.1 points behind SPY at 357.3%. Its deepest 1-year drawdown was 12.7%.

ALPS Medical Breakthroughs ETF is an index-tracking fund that invests at least 80% of its assets in small and mid-cap biotechnology companies with drugs in Phase II or Phase III of FDA clinical trials. The fund does not currently distribute income to shareholders and carries an expense ratio of 0.50%. This ETF appeals to growth-oriented investors seeking exposure to early-stage drug development in the biotech sector.

SBIO key facts

Issuer
ALPS
Asset type
ETF
Asset class
Equity
Expense ratio
0.50%
Distribution frequency
Annual
Last close
$67.28
AUM
$201,617,999
Average volume
34800.0
Ex-dividend date
12/19/2024
Payment date
12/26/2024
Beta
0.97